Skip to content

Study · Randomized controlled trial · n = 37 · 2024

10 results

Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study.

Omachi T, Ohara M, Fujikawa T, Kohata Y, Sugita H, Irie S, Terasaki M, Mori Y, Fukui T, Yamagishi SI

Diabetes therapy : research, treatment and education of diabetes and related disorders25 Oct 2023Cited by 7 (Europe PMC)

PMID37880502 (opens in a new tab)PMCIDPMC10786762 (opens in a new tab)DOI10.1007/s13300-023-01493-3 (opens in a new tab)PepBankPUB-37880502
Read at sourcePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, switching to semaglutide reduced oxidative stress more than continuous dulaglutide.

    In plain wordsIn patients with T2DM, switching to semaglutide reduced oxidative stress more than continued dulaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseOxidative stress
    Study

    n = 37

    Comparator
    Continuous dulaglutide
    Analysis
    Primary
    Outcome group
    Oxidative stress · Whole body
    Studied dose
    Dose not stated · injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Switching to semaglutide therapy was better than continuous dulaglutide therapy in reducing oxidative stress, glucose variability, and glycated hemoglobin levels.
    2 context sentences
    Summary · context
    This is an open-label, multicenter, randomized, prospective, parallel-group comparison study.
    Summary · context
    Overall, 37 patients with T2DM treated with dulaglutide for at least 12 weeks were randomized into two groups: one receiving continuous dulaglutide therapy (n = 19) and one receiving injectable semaglutide therapy (n = 18) groups.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, continuous dulaglutide produced less reduction in oxidative stress than switching to semaglutide.

    In plain wordsIn patients with T2DM, continued dulaglutide reduced oxidative stress less than switching to semaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseOxidative stress
    Study

    n = 37

    Comparator
    Switch to semaglutide
    Analysis
    Primary
    Outcome group
    Oxidative stress · Whole body
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Switching to semaglutide therapy was better than continuous dulaglutide therapy in reducing oxidative stress, glucose variability, and glycated hemoglobin levels.
    2 context sentences
    Summary · context
    This is an open-label, multicenter, randomized, prospective, parallel-group comparison study.
    Summary · context
    Overall, 37 patients with T2DM treated with dulaglutide for at least 12 weeks were randomized into two groups: one receiving continuous dulaglutide therapy (n = 19) and one receiving injectable semaglutide therapy (n = 18) groups.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, switching to semaglutide reduced glucose variability more than continuous dulaglutide.

    In plain wordsIn patients with T2DM, switching to semaglutide reduced glucose variability more than continued dulaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlucose variability
    Study

    n = 37

    Comparator
    Continuous dulaglutide
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Switching to semaglutide therapy was better than continuous dulaglutide therapy in reducing oxidative stress, glucose variability, and glycated hemoglobin levels.
    2 context sentences
    Summary · context
    This is an open-label, multicenter, randomized, prospective, parallel-group comparison study.
    Summary · context
    Overall, 37 patients with T2DM treated with dulaglutide for at least 12 weeks were randomized into two groups: one receiving continuous dulaglutide therapy (n = 19) and one receiving injectable semaglutide therapy (n = 18) groups.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, continuous dulaglutide produced less reduction in glucose variability than switching to semaglutide.

    In plain wordsIn patients with T2DM, continued dulaglutide reduced glucose variability less than switching to semaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseGlucose variability
    Study

    n = 37

    Comparator
    Switch to semaglutide
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Switching to semaglutide therapy was better than continuous dulaglutide therapy in reducing oxidative stress, glucose variability, and glycated hemoglobin levels.
    2 context sentences
    Summary · context
    This is an open-label, multicenter, randomized, prospective, parallel-group comparison study.
    Summary · context
    Overall, 37 patients with T2DM treated with dulaglutide for at least 12 weeks were randomized into two groups: one receiving continuous dulaglutide therapy (n = 19) and one receiving injectable semaglutide therapy (n = 18) groups.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, continuous dulaglutide produced better DTSQ Convenience scores than semaglutide.

    In plain wordsIn patients with T2DM, continued dulaglutide produced better convenience scores than semaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseDTSQ Convenience score
    Study

    n = 37

    Comparator
    Switch to semaglutide
    Analysis
    Secondary
    Outcome group
    Patient-reported outcomes · Whole body
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Conversely, continuous dulaglutide therapy was better than semaglutide therapy in terms of DTSQ scores for "Convenience" and "Recommend."
    2 context sentences
    Summary · context
    This is an open-label, multicenter, randomized, prospective, parallel-group comparison study.
    Summary · context
    Overall, 37 patients with T2DM treated with dulaglutide for at least 12 weeks were randomized into two groups: one receiving continuous dulaglutide therapy (n = 19) and one receiving injectable semaglutide therapy (n = 18) groups.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, semaglutide produced worse DTSQ Convenience scores than continuous dulaglutide.

    In plain wordsIn patients with T2DM, semaglutide produced worse convenience scores than continued dulaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseDTSQ Convenience score
    Study

    n = 37

    Comparator
    Continuous dulaglutide
    Analysis
    Secondary
    Outcome group
    Patient-reported outcomes · Whole body
    Studied dose
    Dose not stated · injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Conversely, continuous dulaglutide therapy was better than semaglutide therapy in terms of DTSQ scores for "Convenience" and "Recommend."
    2 context sentences
    Summary · context
    This is an open-label, multicenter, randomized, prospective, parallel-group comparison study.
    Summary · context
    Overall, 37 patients with T2DM treated with dulaglutide for at least 12 weeks were randomized into two groups: one receiving continuous dulaglutide therapy (n = 19) and one receiving injectable semaglutide therapy (n = 18) groups.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, continuous dulaglutide produced better DTSQ Recommend scores than semaglutide.

    In plain wordsIn patients with T2DM, continued dulaglutide produced better recommendation scores than semaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseDTSQ Recommend score
    Study

    n = 37

    Comparator
    Switch to semaglutide
    Analysis
    Secondary
    Outcome group
    Patient-reported outcomes · Whole body
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Conversely, continuous dulaglutide therapy was better than semaglutide therapy in terms of DTSQ scores for "Convenience" and "Recommend."
    2 context sentences
    Summary · context
    This is an open-label, multicenter, randomized, prospective, parallel-group comparison study.
    Summary · context
    Overall, 37 patients with T2DM treated with dulaglutide for at least 12 weeks were randomized into two groups: one receiving continuous dulaglutide therapy (n = 19) and one receiving injectable semaglutide therapy (n = 18) groups.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, semaglutide produced worse DTSQ Recommend scores than continuous dulaglutide.

    In plain wordsIn patients with T2DM, semaglutide produced worse recommendation scores than continued dulaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseDTSQ Recommend score
    Study

    n = 37

    Comparator
    Continuous dulaglutide
    Analysis
    Secondary
    Outcome group
    Patient-reported outcomes · Whole body
    Studied dose
    Dose not stated · injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Conversely, continuous dulaglutide therapy was better than semaglutide therapy in terms of DTSQ scores for "Convenience" and "Recommend."
    2 context sentences
    Summary · context
    This is an open-label, multicenter, randomized, prospective, parallel-group comparison study.
    Summary · context
    Overall, 37 patients with T2DM treated with dulaglutide for at least 12 weeks were randomized into two groups: one receiving continuous dulaglutide therapy (n = 19) and one receiving injectable semaglutide therapy (n = 18) groups.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, switching to semaglutide reduced glycated hemoglobin more than continuous dulaglutide.

    In plain wordsIn patients with T2DM, switching to semaglutide reduced glycated hemoglobin more than continued dulaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlycated hemoglobin
    Study

    n = 37

    Comparator
    Continuous dulaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · injection · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Switching to semaglutide therapy was better than continuous dulaglutide therapy in reducing oxidative stress, glucose variability, and glycated hemoglobin levels.
    2 context sentences
    Summary · context
    This is an open-label, multicenter, randomized, prospective, parallel-group comparison study.
    Summary · context
    Overall, 37 patients with T2DM treated with dulaglutide for at least 12 weeks were randomized into two groups: one receiving continuous dulaglutide therapy (n = 19) and one receiving injectable semaglutide therapy (n = 18) groups.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In patients with T2DM, continuous dulaglutide produced less reduction in glycated hemoglobin than switching to semaglutide.

    In plain wordsIn patients with T2DM, continued dulaglutide reduced glycated hemoglobin less than switching to semaglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseGlycated hemoglobin
    Study

    n = 37

    Comparator
    Switch to semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Switching to semaglutide therapy was better than continuous dulaglutide therapy in reducing oxidative stress, glucose variability, and glycated hemoglobin levels.
    2 context sentences
    Summary · context
    This is an open-label, multicenter, randomized, prospective, parallel-group comparison study.
    Summary · context
    Overall, 37 patients with T2DM treated with dulaglutide for at least 12 weeks were randomized into two groups: one receiving continuous dulaglutide therapy (n = 19) and one receiving injectable semaglutide therapy (n = 18) groups.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.